Market closed

Annexon/$ANNX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Annexon

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Ticker

$ANNX
Trading on

Industry

Biotechnology

Employees

84

Annexon Metrics

BasicAdvanced
$550M
Market cap
-
P/E ratio
-$1.00
EPS
1.23
Beta
-
Dividend rate
$550M
1.23
$8.40
$2.27
1.3M
17.175
16.967
8.195
8.93
-28.24%
-48.12%
1.65
1.65
-5.761
-47.36%
-30.98%

What the Analysts think about Annexon

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Annexon stock.

Annexon Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Annexon Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ANNX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Annexon stock?

Annexon (ANNX) has a market cap of $550M as of November 22, 2024.

What is the P/E ratio for Annexon stock?

The price to earnings (P/E) ratio for Annexon (ANNX) stock is 0 as of November 22, 2024.

Does Annexon stock pay dividends?

No, Annexon (ANNX) stock does not pay dividends to its shareholders as of November 22, 2024.

When is the next Annexon dividend payment date?

Annexon (ANNX) stock does not pay dividends to its shareholders.

What is the beta indicator for Annexon?

Annexon (ANNX) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.